MDH2 and prostate carcinoma: In addition, Liu et al.'s study revealed that MDH2 mediates prostate cancer resistance to docetaxel-chemotherapy through JNK pathway and MDH2 knockdown significantly enhanced the docetaxel sensitivity in prostate cancer cells.